 Clinical Oncology News | Fludarabine Plus Rituximab Assessed in Relapsed/Refractory HCL Clinical Oncology News A team of researchers from Vancouver, British Columbia, has found that treatment with combination therapy of fludarabine (Fludara, Genzyme; various) and rituximab (Rituxan, Genentech) produces positive outcomes—as measured by progression-free survival ... |
